Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MYLS22 is a first-in-class and selective inhibitor of optic atrophy 1 (OPA1) . MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. It with anti-angiogenesis and anti-cancer activity.
説明 | MYLS22 is a first-in-class and selective inhibitor of optic atrophy 1 (OPA1) . MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression. It with anti-angiogenesis and anti-cancer activity. |
In vivo | MYLS22 (10 mg/kg/die;?peritumoral injection;?every 2 days for 14 days) causes the tumor growth curtailed mice |
分子量 | 443.52 |
分子式 | C24H21N5O2S |
CAS No. | 306959-01-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (101.46 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MYLS22 306959-01-3 Others OPA1 Inhibitor optic atrophy MYLS 22 endothelial inhibit tumor MYLS-22 inhibitor